Member Info for iaintgotaclu

From the RNS they dont need money so no raise coming

"The Company remains very positive about the potential of Licence PL001. We have sufficient cash reserves to meet our ongoing requirements. Now that the reassignment of the Licence has been completed the Company will work to secure other partners to participate in its development".

ok brilliant thanks now move on

lol caught short

BOOOOOOOOOOOOOOOOOOOM

can buy for 3.29

all about being in early guys

https://twitter.com/riddler_smitb/status/1098507595847995392

Been missed holders of SKIN which has rose 200%

Latino no i am not mate they hold shares here do some research

Helium Rising Stars 42,762,295 9.40%
Venn Life Sciences 42,244,672 9.29%
Enhance 29,488,144 6.48%
Medinova 27,248,440 5.99%
Chess Group 20,818,182 4.58%

Venn life still to make its massive move as they are holding these so got to adjust could be a way of getting in lower

VENN catching up as the penny dropped they hold this share

1.5 mill buy delayed slightly

i see no Resistance till 21p

Down to the yanks now till the morning

https://stocktwits.com/symbol/MTFB

Spread tightening

there you go anther 3.5 million sell

still another big sell or 2 to come price holding steady, does anyone know who is holding and how many

Motif Bio Plc (LON:MTFB, NASDAQ:MFTB) said it has requested a meeting with the Food & Drug Administration after the US watchdog said it wouldn’t be giving the regulatory green light to the company’s antibiotic, iclaprim.

In what’s called a complete response letter, the FDA indicated additional data would be required “to further evaluate the risk for liver toxicity” before granting approval.

Motif, which developed the treatment for acute bacterial skin and skin structure infections, said it is keen to “to discuss potential options to address the deficiencies”. According to chief executive Graham Lumsden, his team may have to wait between 30-45 days before having the opportunity to do so.

"We look forward to working with the agency to discuss options to advance iclaprim towards approval," he said.

https://www.proactiveinvestors.co.uk/companies/news/214611/motif-bio-seeks-talks-with-fda-after-iclaprim-setback-214611.html

Jimzi exactly what has happened here

no live mate on level 2